12:00 AM
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tedizolid phosphate regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation for IV and oral tedizolid to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). The second-generation oxazolidinone, a bacterial protein biosynthesis inhibitor, is in Phase III testing to treat ABSSSI. The company...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >